Observation on the Efficacy and Mechanism of SLIT With Dust Mite Allergen for PAR

Study Overview
=================
Brief Summary
-----------------
Allergic rhinitis is a common and recurrent ear, nose and throat (ENT) disease. It is a chronic or seasonal condition affecting 10% to 20% of the world's population. It is considered one of the most difficult diseases to treat globally and has become a major global health problem. SUblingual immunotherapy (SIT) is currently considered to be an effective pairings therapy that can alter the natural progression of allergic rhinitis through immunomodulatory mechanisms. Immunotherapy is more suitable for patients with moderate to severe intermittent or persistent allergic rhinitis, especially for those with poor drug treatment. This treatment can significantly reduce the severity of allergic rhinitis, reduce the use of allergy medications, and improve the quality of life for many patients. In the development of allergic rhinitis, the regulation of immune balance in Th1 / Th2 / Th17 cells is currently considered to be an important approach in the treatment of allergic rhinitis. But a growing body of evidence suggests that an intrinsic immune response is also the pathogenesis of allergic rhinitis. Innate lymphocytes are involved in mucosal immune formation, lymphocyte development, tissue damage repair and epithelial barrier protection, and play an important role in fighting infection, regulating inflammation and maintaining immune homeostasis. Three subsets of intrinsic lymphocytes (ILC1s, ILC2s, ILC3s) have been proposed to functionally approximate Th1, Th2, and Th17 in helper T lymphocytes (Th), but the results are inconclusive and the mechanism of ILCs role in AR progression is not fully elucidated. Therefore, the purpose of this study was to investigate the efficacy and mechanism of subglossal immunotherapy for perennial allergic rhinitis, and to reveal the correlation between ILCs (ILC1s, ILC2s, ILC3s) and Th1 / Th2 / Th17 cell immunity, and to provide a basis for clinical studies of allergic rhinitis.

Detailed Description
-----------------
Allergic rhinitis (AR) has become a major chronic respiratory inflammatory disease and is considered to be one of the global refractory diseases. and it has become an important global health problem. The treatment of AR mainly includes environmental control, drug therapy, immunotherapy, etc. Studies have shown that the positive rate of dust mite allergen skin prick test in AR patients can reach 70%. Dust mites are considered to be the main allergens causing allergic diseases such as allergic rhinitis and asthma, which are ubiquitous in clinical living environments. Since it is difficult for patients to completely avoid exposure to dust mites in real life, it has attracted more and more attention of scholars to change the allergic constitution of patients by Specific immunotherapy SIT. Specific immunotherapy is currently considered to be a more certain therapeutic approach in addition to allergen avoidance, which is the etiological treatment for IgE-mediated type I allergic disease. To gradually increase the dose of allergen extracts, gradually induced the body's immune tolerance, achieve when again contact allergens in patients with symptoms significantly reduce, or even not occur, the effect of this effect at the end of the treatment with sustainable for several years, is considered the only can be adjusted by the immune mechanism to change the allergic disease effective method for treatment of natural processes, Its safety and efficacy have been proved in clinical treatment by modifying immune function to change disease progression. Currently, SIT mainly consists of Subcutaneous immunotherapy (SCIT) and Sublingual immunotherapy (SLIT), which is divided into dose accumulation and dose maintenance phases. Standardized allergenic vaccines should be used for immunotherapy. This therapy can significantly reduce the severity of AR, reduce the use of anti-allergic drugs, and improve the quality of life of many patients. Especially for children, immunotherapy can not only reduce allergic symptoms, but also prevent the development of allergic rhinitis to asthma and other severe sensitization reactions. According to the AR recognition guidelines, immunotherapy is more suitable for patients with moderate-severe intermittent or persistent AR, especially for those with poor drug treatment effect. Compared with SCIT, SLIT is relatively simple to operate, non-invasive, well tolerated and safe. The risk of systemic adverse reactions is low. In addition, allergen vaccines can be administered at home by patients or guardians under the guidance of doctors, which reduces the frequency of hospital visits, thus being highly recommended by clinical practice. The allergen vaccine of SLIT is mainly dust mite drops in China. The application of Sublingual immunotherapy of dust mite allergen in the clinical treatment of AR began in 1986. The way of administration of Sublingual immunotherapy is different from subcutaneous immunotherapy: allergen vaccine is placed under the tongue, swallowed after several minutes of absorption, and the vaccine is ingested into the body through the oral mucosa. In 1993, the European Society of Clinical Immunology and Allergy proposed that sublingual immunotherapy was safer and more effective than subcutaneous immunotherapy. In 1998, SLIT was proposed by WHO to be used for adult allergic rhinitis. In 2001, the ARIA group of the World Health Organization pointed out that SLIT can effectively treat AR and patients can reduce the use of drugs, which has led to SLIT receiving increasing attention worldwide. In 2013, the World Allergy Organization (WAO) not only affirmed the clinical efficacy and safety of SLIT in its position paper, but also recommended SLIT as an initial and early clinical treatment for allergic diseases. Its application does not need to be based on the premise of drug treatment failure. Allergen-specific immunotherapy was proposed as the first-line therapy for AR in the 2015 new edition of Chinese guidelines, which is recommended for clinical use. Allergic rhinitis is a non-infectious chronic inflammatory disease of nasal mucosa mainly mediated by immunoglobulin E (IgE) after atopic individuals are exposed to allergens. According to the type of allergen, AR can be divided into seasonal and perennial. According to the course of disease can be divided into intermittent and persistent; The impact on quality of life is divided into mild and moderate-severe. Current studies have shown that Th1 / Th2 / Th17 cell immune imbalance is an important mechanism of AR pathogenesis. In the development of AR, T cells are the only cells that directly react with antigen. Helper T lymphocytes Th cells are derived from precursor cells that produce InterLeukin-2. After initial stimulation, these cells develop into Th0 cells (CD4+T cells). It can produce interferon-γ (IFN-γ), IL-2, IL-4 and IL-5, and Th0 cells can be differentiated into Th1 cells under the induction of IL-12 and IFN-γ according to the action of cytokines. It secretes IFN-γ, IL-2 and Tumor necrosis factor β (TNF-β) to participate in cellular immune response. Under the induction of IL-4, they differentiate into Th2 cells and secrete IL-4, IL-5, IL-13, IL-8 and other cytokines to participate in humoral immune response. Th17 is a new type of T helper lymphocyte, which is a pro-inflammatory cell that can activate the body's inflammatory response and participate in the regulation of the autoimmune system. It was discovered in 2003 and got its name because it can secrete iconic factors such as IL-17 and IL-23, and it plays an important role in the body's self-immune response. In the occurrence and development of AR, IFN-γ, IL-4 and IL-17 are the main effectors of Th1, Th2 and Th17 respectively. It has been reported that IL-4 immune inflammatory factor released by Th2 cells has a regulatory effect on the level of IgE. However, IFN-γ released by Th1 cells has an inhibitory effect on IL-4 secretion by Th2 cells. Il-17 is a cytokine secreted by Th17 cells with strong proinflammatory effect. Serum IL-17 in patients is positively correlated with IgE level, and its increased level can be used as an indicator for the diagnosis of AR. Therefore, regulating the immune balance of Th1 / Th2 / Th17 cells is an important way to treat AR. However, increasing evidence shows that innate immune response is also the pathogenesis of AR. The innate immune system is the first line of defense against invading pathogens or antigens, and its response is rapid and non-specific. Subsequently, the activated adaptive immune system performs complete elimination of specific antigens. Innate lymphoid cells (ILCs), as an important effector cell population of Innate immunity, are characterized by three major characteristics: they do not undergo receptor gene rearrangement and clonal selection, lack of phenotypic markers of myeloid cells and dendritic cells, and their morphology belongs to the lymphoid lineage. ILCs are mostly tissue-resident lymphocytes, mainly distributed in the tonsil, broncho-lung, intestinal tract, skin and other mucosal barrier sites. ILCs are involved in mucosal immune formation, lymphocyte development, tissue damage repair and epithelial barrier protection, and play an important role in fighting infection, regulating inflammation and maintaining immune homeostasis. According to the phenotype and cytokines secreted by ILCs, ILCs can be divided into 3 subsets of type 1, 2 and 3 innate lymphocytes (ILC1s, ILC2s and ILC3s), which are functionally approximately corresponding to Th1, Th2 and Th17 of Th cells. ILC1s includes natural killer cells (NK) and ILC1 cells, which depend on T-box transcription factor (T-BET) and produce large amounts of interferon (IFN-γ) and tumor necrosis factor-α (TNF-α). The development of ILC2s depends on the transcription factor GATA3 to produce Th2-type cytokines and other effector molecules, such as IL-4, IL-5, IL-9, IL-13 and vascular endothelial growth factor (VEGF), which drive the development of type 2 immune response. Moreover, unlike T cells, which recognize specific antigens, ILC2s respond to nonspecific cytokines, including IL-25, IL-33, and Thymic stromal lymphocytes produce hormone. TSLP can stimulate the activation and proliferation of ILC2s to produce a large amount of IL-5 and IL-13, resulting in airway inflammation and airway hyperresponsiveness. ILC3s depend on the transcription factor RORTt to produce cytokines IL-17 and IL-22 similar to Th17. Some studies have found that after the nasal epithelium of AR patients is stimulated by allergens, the pro-inflammatory cytokines in the epithelium increase, and IL-25, IL-33 and TSLP can be detected in the nasal lavage fluid of patients with house dust mite (HDM) allergy. However, the level of IL-25 released by peripheral blood mononuclear cells (PBMC) will be up-regulated after basophils of birch and pollen allergy patients are stimulated by allergens. Have the study showed that the amount of ILC2 in nasal epithelial cells of patients with allergic fungal sinusitis increased and was positively regulated by IL-25 derived from epithelial cells, which were positively correlated with the expression levels of IL-5 and IL-13 in nasal mucosa. Other studies have shown that the number of ILC2 in peripheral blood of patients with HDM allergy is increased, and its number change is positively correlated with the severity of symptoms. Studies on AR caused by plant allergens found that during the grass pollen season, the number of ILC2 and ILC3 in peripheral blood of patients with grass pollen allergy increased, while the number of ILC1 did not change significantly. However, other study found that the number of ILC2 in peripheral blood of AR patients did not increase, but that of asthma patients increased. There is no consensus on whether the number of ILC2s in peripheral blood of AR patients is increased. In conclusion, the mechanism of AR is mainly related to the imbalance of Th1 / Th2 / Th17 cell immunity, but more and more evidence shows that innate immune response is also the pathogenesis of AR, and the specific mechanism of ILCs in the development of AR has not been fully elucidated. In conclusion, the mechanism of AR is mainly related to the imbalance of Th1 / Th2 / Th17 cell immunity, but more and more evidence shows that innate immune response is also the pathogenesis of AR, and the specific mechanism of ILCs in the development of AR has not been fully elucidated. Therefore, this study aims to explore the efficacy of sublingual desensitization in the treatment of perennial allergic rhinitis and its mechanism of action on ILCs, reveal the correlation between ILCs (ILC1s, ILC2s, ILC3s) and Th1 / Th2 / Th17 cell immunity, and provide research basis for clinical research on AR.

Official Title
-----------------
Observation on the Efficacy of Sublingual Immunotherapy With Dust Mite Allergen for Perennial Allergic Rhinitis and the Mechanism of Action on ILCs With ILC1s and ILC2s and ILC3s

Conditions
-----------------
Allergic Rhinitis

Intervention / Treatment
-----------------
* Drug: Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Those who meet the above diagnostic criteria; The course of disease is at least one year; Over 18 years old to under 65 years old, both sexes; Did not receive specific immunotherapy in the past 1 month or did not use any drugs for AR in the past 1 week; Those with normal cognitive function agree to participate in this study and sign the informed consent form. Exclusion Criteria: Those who do not meet the above diagnostic and inclusion criteria; Patients with severe nasal septum deviation, chronic rhinosinusitis, bronchial asthma, nasal polyps, upper respiratory tract infection, lung infection and other diseases; Patients with severe dysfunction of heart, liver, kidney or autoimmune diseases; pregnant or lactating women; Allergic constitution and allergic to the experimental drugs and ingredients; Patients with drug addiction history; Patients with major neuropsychiatric diseases who cannot take medication regularly; Patients who are participating in other clinical trials. Patients who met any of the above criteria were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: We will be collected 60 subjects and randomize them into two groups, the trial group and control group. The QC will use a computerized randomization method using EXCEL software to generate random numbers using a RAND function (a total of 60 random numbers). Sixty randomly selected subjects will have a 1 / 2 chance of being randomly assigned to either the experimental or control groups. Patients were randomly assigned to appropriate groups and treatment regimens based on a random number of visits.
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: In the control group<br>Half of the subjects（30 subjects）will be assigned to the control group，they will be using the Mometasone furoate nasal spray (Nasonex). | Drug: Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).<br>* The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.<br>* Other names: Brucelated mamisone nasal spray, consisting mainly of an antacid mamisone, measuring 10ml, 50μg x 60 press (0.05%).;|
| Experimental: The experimental group<br>Half of the subjects (30) will be assigned to the experimental group. Received sublingual dust mite drops (trade name: Changdi, Zhejiang Wuwu Biotechnology Co., LTD.) for sublingual immunotherapy. | Drug: Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).<br>* The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.<br>* Other names: Brucelated mamisone nasal spray, consisting mainly of an antacid mamisone, measuring 10ml, 50μg x 60 press (0.05%).;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in total nasal symptom score scale | The total nasal symptom score scale will be collected. | Baseline, 1 month, 3 months | 
| Change in Visual analogue scale | Visual analogue scale will be collected. | Baseline, 1 month, 3 months | 
| Change in the quality by life questionnaire of rhinoconjunctivitis | Quality of life questionnaire of rhinoconjunctivitis will be collected. | Baseline, 1 month, 3 months | 
| Change in the Serum levels of IgE | Serum samples will be collected the levels of IgE | Baseline, 1 month, 3 months | 
| Change in the Serum levels of IFN-γ | Serum samples will be collected the levels of IFN-γ. | Baseline, 1 month, 3 months | 
| Change in the Serum levels of IL-4 | Serum samples will be collected the levels of IL-4. | Baseline, 1 month, 3 months | 
| Change in the Serum levels of IL-17 | Serum samples will be collected the levels of IL-17. | Baseline, 1 month, 3 months | 
| Change in the Serum levels of TNF-α | Serum samples will be collected the levels of TNF-α. | Baseline, 1 month, 3 months | 
| Change in the Serum levels of IL-5 | Serum samples will be collected the levels of IL-5. | Baseline, 1 month, 3 months | 
| Change in the Serum levels of IL-9 | Serum samples will be collected the levels of IL-9. | Baseline, 1 month, 3 months | 
| Change in the Serum levels of IL-13 | Serum samples will be collected the levels of IL-13. | Baseline, 1 month, 3 months | 
| Change in the Serum levels of IL-25 | Serum samples will be collected the levels of IL-25. | Baseline, 1 month, 3 months | 
| Change in the Serum levels of IL-33 | Serum samples will be collected the levels of IL-33. | Baseline, 1 month, 3 months | 
| Change in the Serum levels of VEGF | Serum samples will be collected the levels of VEGF. | Baseline, 1 month, 3 months | 
| Change in the Serum levels of TSLP | Serum samples will be collected the levels of TSLP. | Baseline, 1 month, 3 months | 
| Change in the Serum levels of IL-22 | Serum samples will be collected the levels of IL-22. | Baseline, 1 month, 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To reveal the correlation between ILCs (ILC1s, ILC2s, ILC3s) and Th1 / Th2 / Th17 cell immunity | To reveal the correlation between ILCs (ILC1s, ILC2s, ILC3s) and Th1 / Th2 / Th17 cell immunity To explore the efficacy and mechanism of sublingual desensitization in the treatment of perennial allergic rhinitis, and to reveal the correlation between ILCs(ILC1s, ILC2s, ILC3s) and Th1 / Th2 / Th17 cell immunity | 3 months after treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AR (Allergic rhinitis), PAR (perennial allergic rhinitis ), SLIT (Sublingual immunotherapy), ILCs (Innate lymphoid cells), Curative effect, Discussion on mechanism